Investigation of the effects and mechanisms of action of different wavelengths of ultraviolet B (UVB) radiation in the treatment of psoriasis
| ISRCTN | ISRCTN43688684 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN43688684 |
| Protocol serial number | 5623; 079504 |
| Sponsor | Newcastle upon Tyne Hospitals NHS Foundation Trust (UK) |
| Funder | The Wellcome Trust (UK) (grant ref: 079504) |
- Submission date
- 12/05/2010
- Registration date
- 12/05/2010
- Last edited
- 13/12/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Skin and Connective Tissue Diseases
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Newcastle University
Dermatology
2nd Floor William Leech Building
Medical School
Newcastle
NE2 4HH
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Single centre non-randomised interventional treatment trial |
| Secondary study design | Non randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Investigation of the effects and mechanisms of action of different wavelengths of ultraviolet B (UVB) radiation in the treatment of psoriasis: a single centre non-randomised treatment trial |
| Study acronym | MECH-UVB-PSOR |
| Study objectives | To test the hypothesis that keratinocyte apoptosis is an important mechanism of action of ultraviolet B (UVB) phototherapy in the clearance of psoriasis, and to investigate the correlation between effectiveness of different wavelengths of UV and apoptotic response in the clearance of psoriasis. |
| Ethics approval(s) | County Durham and Tees Valley (1) REC, ref: 06/Q1003/78 |
| Health condition(s) or problem(s) studied | Topic: Skin; Subtopic: Skin (all Subtopics); Disease: Dermatology |
| Intervention | Compare the apoptotic effect of different wavelengths of UVB in psoriatic epidermis in vivo. |
| Intervention type | Other |
| Primary outcome measure(s) |
Whether the number of apoptotic cells seen within the epidermis is sufficient to allow plaque remodelling. Measured up to 48 hours (4 hours, 8 hours, 12 hours,15 hours, 18 hours, 24 hours, and 48 hours). |
| Key secondary outcome measure(s) |
1. Effect of skin type |
| Completion date | 30/04/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 121 |
| Key inclusion criteria | 1. Aged 18 years and over, with no sex specific criteria 2. All patients who are prescribed routine UVB (TL01) for their psoriasis at our centre 3. Give informed consent to participate |
| Key exclusion criteria | 1. Aged under 18 years 2. Systemic immunosupression within 3 months 3. UVB exposure to lower back within 3 months of recruitment 4. Topical treatments other than emollients for 2 weeks |
| Date of first enrolment | 01/10/2006 |
| Date of final enrolment | 30/04/2010 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
NE2 4HH
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
13/12/2019: No publications found, verifying study status with principal investigator.
09/05/2016: No publications found, verifying study status with principal investigator.
